아스트라제네카 코로나19 백신(ChAdOx1 nCoV-19/AZD1222)을 접종한 환자에서 한방 치료의 안전성 : 사례군 연구 = Safety of Korean Medicine Treatment in Patients Vaccinated with the AstraZeneca COVID-19 Vaccine (ChAdOx1 nCoV-19/AZD1222): A Case Series

다국어 초록 (Multilingual Abstract)

Objectives: The purpose of this study is to examine the safety of Korean medicine treatment in patients vaccinated with the AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19/AZD1222). Methods: We investigated patients at Kyung Hee University Korean Medicine Hospital who were vaccinated with the AstraZeneca COVID-19 vaccine between June 1, 2021 and June 30, 2021. The safety of Korean medicine treatment was evaluated by examining adverse events that occurred within seven days of vaccination, including liver function and kidney function testing, assessment of the severity of adverse events, and examination of causality to vaccines and Korean medicine treatment. Results: Eleven patients vaccinated with the first dose of the AstraZeneca COVID-19 vaccine were included. A total of 19 adverse events were reported: 15 systemic adverse events, three local adverse events, and one alanine aminotransferase increase. The most commonly reported systemic adverse events were fatigue (4 cases, 36.4%), headache (4 cases, 36.4%), and myalgia (4 cases, 36.4%). All adverse events were rated below moderate (grade 2) in severity. Systemic and local adverse events were evaluated as definitely related to vaccination and unlikely to be related to Korean medicine treatment, while alanine aminotransferase increase was evaluated as unlikely to be related to either the vaccine or Korean medicine treatment. Aspartate transaminase, Blood urea nitrogen, and creatinine were measured within the reference range after vaccination. Conclusion: Our results suggest that the severity and frequency of adverse events in patients vaccinated with the AstraZeneca COVID-19 vaccine did not increase after Korean medicine treatment.

참고문헌 (Reference)

1 European Medicines Agency, "Vaxzevria (previously COVID-19 Vaccine AstraZeneca) : EPAR -Public assessment report"

2 World Health Organization-Uppsala Monitoring Centre, "The use of the WHO-UMC system for standardised case causality assessment"

3 Wang D, "The Adjuvant Effects on Vaccine and the Immunomodulatory Mechanisms of Polysaccharides From Traditional Chinese Medicine" 8 : 655570-, 2021

4 World Health Organization, "Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barré Syndrome (GBS)following adenovirus vector COVID-19 vaccines"

5 Voysey M, "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222)vaccine: a pooled analysis of four randomised trials" 397 (397): 881-891, 2021

6 Folegatti PM, "Safety and immunogenicity of the ChAdOx1 nCoV-19vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial" 396 (396): 467-478, 2020

7 Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK" 397 (397): 99-111, 2021

8 Connors M, "SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn" 174 (174): 687-690, 2021

9 Nam Dj, "Review about the Study of Ssanghwa-tang Published in Korea from 2000to 2019" 28 (28): 12-19, 2019

10 World Health Organization, "Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine"

11 World Health Organization, "Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19vaccine AZD1222 Vaxzevria™, SII COVISHIELDTM)"

12 Lin Ang, "Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines" 한국한의학연구원 9 (9): 1-14, 2020

13 Ministry of Food and Drug Safety, "Guidelines for evaluating severity of adverse reactions in vaccine clinical trials"

14 US Food and Drug Administration, "Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials"

15 Andrade RJ, "EASL Clinical Practice Guidelines: Drug-induced liver injury" 70 (70): 1222-1261, 2019

16 Peltier E, "Denmark says it’s permanently stopping use of the AstraZeneca vaccine"

17 Huang J, "Current Prevention of COVID-19: Natural Products and Herbal Medicine" 11 : 588508-, 2020

18 World Health Organization, "Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca"

19 European Medicines Agency, "Assessment report COVID-19 vaccine AstraZeneca"

20 Bae Seongman, "Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea" 대한의학회 36 (36): 1-9, 2021

21 Korea Disease Control and Prevention Agency, "Adverse Event Management Guidelines after Coronavirus Disease 19 Vaccination (1-3rd Edition)"

22 Taguchi A, "Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner" 30 (30): 5368-5372, 2012